Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,741 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome.
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. Longbrake EE, et al. Among authors: pei j. Mult Scler Relat Disord. 2022 Dec;68:104143. doi: 10.1016/j.msard.2022.104143. Epub 2022 Aug 22. Mult Scler Relat Disord. 2022. PMID: 36031693 Free PMC article.
Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.
Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Vollmer TL, et al. Among authors: pei j. Mult Scler Relat Disord. 2020 Nov;46:102454. doi: 10.1016/j.msard.2020.102454. Epub 2020 Aug 18. Mult Scler Relat Disord. 2020. PMID: 33045496 Free article. Clinical Trial.
Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.
Cree BAC, Pradhan A, Pei J, Williams MJ; OPERA I and OPERA II clinical investigators. Cree BAC, et al. Among authors: pei j. Mult Scler Relat Disord. 2021 Jul;52:103010. doi: 10.1016/j.msard.2021.103010. Epub 2021 May 7. Mult Scler Relat Disord. 2021. PMID: 34147885 Free article. Clinical Trial.
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, Voloshyna I, Samanovic MI, Cornelius AR, Velmurugu Y, Nyovanie S, Kim JJ, Tardio E, Bacon TE, Zhovtis Ryerson L, Raut P, Pedotti R, Hawker K, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: pei j. Ann Neurol. 2022 Jun;91(6):782-795. doi: 10.1002/ana.26346. Epub 2022 Apr 1. Ann Neurol. 2022. PMID: 35289960 Free PMC article.
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.
Kister I, Curtin R, Pei J, Perdomo K, Bacon TE, Voloshyna I, Kim J, Tardio E, Velmurugu Y, Nyovanie S, Valeria Calderon A, Dibba F, Stanzin I, Samanovic MI, Raut P, Raposo C, Priest J, Cabatingan M, Winger RC, Mulligan MJ, Patskovsky Y, Silverman GJ, Krogsgaard M. Kister I, et al. Among authors: pei j. Ann Clin Transl Neurol. 2022 Oct;9(10):1643-1659. doi: 10.1002/acn3.51664. Epub 2022 Sep 27. Ann Clin Transl Neurol. 2022. PMID: 36165097 Free PMC article.
Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.
Barrera B, Simpson H, Engebretson E, Sillau S, Valdez B, Parra-González J, Winger RC, Epperson LA, Banks A, Pierce K, Spotts M, O'Gean K, Alvarez E, Gross R, Piquet AL, Schreiner T, Corboy JR, Pei J, Vollmer TL, Nair KV. Barrera B, et al. Among authors: pei j. Ann Clin Transl Neurol. 2023 Apr;10(4):579-588. doi: 10.1002/acn3.51745. Epub 2023 Feb 22. Ann Clin Transl Neurol. 2023. PMID: 36811392 Free PMC article. Clinical Trial.
Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E, Yap S, Ndrio J, Pei J, Mowry EM, Magrini F, Acosta J, Amezcua L; CHIMES investigators. Williams MJ, et al. Among authors: pei j. Mult Scler Relat Disord. 2023 Aug;76:104794. doi: 10.1016/j.msard.2023.104794. Epub 2023 Jun 9. Mult Scler Relat Disord. 2023. PMID: 37356256 Free article. Clinical Trial.
Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, Bacon TE, Kim A, Tuen M, Velmurugu Y, Nyovanie S, Selva S, Samanovic MI, Mulligan MJ, Patskovsky Y, Priest J, Cabatingan M, Winger RC, Krogsgaard M, Silverman GJ. Kister I, et al. Among authors: pei j. Ann Clin Transl Neurol. 2024 Jul;11(7):1750-1764. doi: 10.1002/acn3.52081. Epub 2024 May 7. Ann Clin Transl Neurol. 2024. PMID: 38713096 Free PMC article.
2,741 results